See more : Pershing Square Holdings, Ltd. (PSHD.L) Income Statement Analysis – Financial Results
Complete financial analysis of Electromed, Inc. (ELMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Electromed, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- La Rosa Holding Corp. Common Stock (LRHC) Income Statement Analysis – Financial Results
- Biofrontera AG (BFAGY) Income Statement Analysis – Financial Results
- EFG International AG (EFGN.SW) Income Statement Analysis – Financial Results
- Jyske Bank A/S (JYSKF) Income Statement Analysis – Financial Results
- Skanska AB (publ) (SKSBF) Income Statement Analysis – Financial Results
Electromed, Inc. (ELMD)
About Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.72M | 48.07M | 41.66M | 35.76M | 32.47M | 31.30M | 28.70M | 25.86M | 22.99M | 19.41M | 15.49M | 15.10M | 19.52M | 19.00M | 14.30M | 13.00M | 8.75M |
| Cost of Revenue | 12.99M | 11.55M | 10.22M | 8.45M | 7.27M | 7.45M | 5.84M | 5.29M | 5.12M | 5.81M | 4.85M | 4.66M | 5.38M | 5.23M | 3.71M | 3.34M | 2.15M |
| Gross Profit | 41.73M | 36.52M | 31.44M | 27.31M | 25.20M | 23.85M | 22.86M | 20.57M | 17.88M | 13.60M | 10.63M | 10.45M | 14.15M | 13.78M | 10.60M | 9.66M | 6.61M |
| Gross Profit Ratio | 76.26% | 75.98% | 75.47% | 76.36% | 77.61% | 76.19% | 79.64% | 79.53% | 77.75% | 70.07% | 68.66% | 69.18% | 72.45% | 72.50% | 74.08% | 74.30% | 75.47% |
| Research & Development | 656.00K | 916.00K | 1.36M | 1.72M | 1.05M | 583.31K | 251.44K | 596.88K | 380.39K | 315.65K | 466.06K | 603.38K | 920.77K | 1.03M | 600.99K | 357.87K | 271.24K |
| General & Administrative | 33.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 499.00K | 589.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.49M | 31.60M | 27.11M | 22.44M | 19.94M | 20.45M | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 10.87M | 8.20M | 6.85M | 6.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -12.00K | -913.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.87M | 8.20M | 6.85M | 6.00M |
| Operating Expenses | 35.15M | 32.51M | 28.47M | 24.17M | 20.08M | 21.03M | 19.85M | 17.00M | 14.77M | 12.29M | 11.37M | 12.28M | 13.54M | 11.91M | 8.80M | 7.20M | 6.27M |
| Cost & Expenses | 48.14M | 44.06M | 38.69M | 32.62M | 27.35M | 28.48M | 25.69M | 22.29M | 19.88M | 18.10M | 16.23M | 16.93M | 18.92M | 17.13M | 12.51M | 10.54M | 8.42M |
| Interest Income | 455.00K | 78.00K | 25.00K | 39.00K | 120.75K | 90.71K | 0.00 | 17.04K | 0.00 | 284.00 | 12.39K | 16.72K | 8.40K | 10.92K | 6.42K | 8.75K | 24.82K |
| Interest Expense | 0.00 | 0.00 | 25.00K | 0.00 | 0.00 | 0.00 | 19.87M | 66.91K | 66.81K | 85.99K | 91.40K | 133.56K | 177.13K | 191.33K | 269.85K | 279.19K | 501.69K |
| Depreciation & Amortization | 841.00K | 613.00K | 628.00K | 610.00K | 738.23K | 925.23K | 790.03K | 755.13K | 738.70K | 736.22K | 695.55K | 589.86K | 532.63K | 449.47K | 351.75K | 318.95K | 268.40K |
| EBITDA | 7.42M | 4.62M | 3.60M | 3.75M | 5.86M | 3.74M | 3.80M | 4.32M | 3.85M | 2.05M | -32.65K | -1.24M | 1.15M | 2.33M | 2.15M | 2.77M | 627.43K |
| EBITDA Ratio | 13.56% | 9.61% | 8.64% | 10.49% | 18.04% | 11.96% | 13.24% | 16.72% | 16.74% | 10.54% | -0.21% | -8.08% | 5.88% | 12.21% | 15.06% | 21.41% | 7.17% |
| Operating Income | 6.58M | 4.01M | 2.97M | 3.14M | 5.12M | 2.82M | 3.01M | 3.57M | 3.11M | 1.31M | -740.59K | -1.83M | 606.34K | 1.87M | 1.80M | 2.46M | 334.22K |
| Operating Income Ratio | 12.03% | 8.34% | 7.13% | 8.78% | 15.76% | 9.00% | 10.48% | 13.80% | 13.52% | 6.75% | -4.78% | -12.10% | 3.11% | 9.84% | 12.56% | 18.89% | 3.82% |
| Total Other Income/Expenses | 455.00K | 78.00K | 25.00K | 27.00K | 120.75K | 101.82K | -276.35K | -49.87K | -66.81K | -85.71K | -79.00K | -116.88K | -168.73K | -191.33K | -263.43K | -270.45K | -476.87K |
| Income Before Tax | 7.04M | 4.09M | 3.00M | 3.17M | 5.24M | 2.91M | 3.03M | 3.52M | 3.04M | 1.22M | -819.59K | -1.94M | 437.61K | 1.68M | 1.53M | 2.19M | -142.65K |
| Income Before Tax Ratio | 12.86% | 8.50% | 7.19% | 8.86% | 16.14% | 9.29% | 10.55% | 13.61% | 13.23% | 6.31% | -5.29% | -12.87% | 2.24% | 8.83% | 10.71% | 16.81% | -1.63% |
| Income Tax Expense | 1.89M | 920.00K | 692.00K | 805.00K | 1.08M | 940.00K | 1.13M | 1.29M | 830.00K | 132.00K | 469.00K | -615.00K | 251.00K | 623.00K | 599.00K | 830.00K | -427.00K |
| Net Income | 5.15M | 3.17M | 2.31M | 2.36M | 4.16M | 1.97M | 1.90M | 2.23M | 2.21M | 1.09M | -1.29M | -1.33M | 186.61K | 1.06M | 916.34K | 1.33M | 267.85K |
| Net Income Ratio | 9.41% | 6.59% | 5.53% | 6.61% | 12.81% | 6.29% | 6.63% | 8.62% | 9.62% | 5.63% | -8.32% | -8.80% | 0.96% | 5.55% | 6.41% | 10.25% | 3.06% |
| EPS | 0.60 | 0.37 | 0.27 | 0.28 | 0.50 | 0.24 | 0.23 | 0.27 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.14 | 0.15 | 0.22 | 0.05 |
| EPS Diluted | 0.58 | 0.36 | 0.26 | 0.27 | 0.47 | 0.23 | 0.22 | 0.26 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.13 | 0.15 | 0.22 | 0.04 |
| Weighted Avg Shares Out | 8.56M | 8.46M | 8.47M | 8.57M | 8.40M | 8.31M | 8.21M | 8.17M | 8.14M | 8.12M | 8.05M | 8.11M | 8.11M | 7.82M | 6.08M | 5.99M | 5.44M |
| Weighted Avg Shares Out (Dil) | 8.86M | 8.70M | 8.77M | 8.91M | 8.83M | 8.63M | 8.62M | 8.46M | 8.25M | 8.15M | 8.11M | 8.11M | 8.11M | 7.84M | 6.11M | 6.02M | 6.45M |
Electromed, Inc. Schedules its Fourth Quarter Fiscal 2020 Financial Results Conference Call for August 25, 2020 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2020 fourth quarter ended June 30, 2020...
Summers Value Partners Q2 2020 Investor Letter
Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate.
Electromed (NYSEAMERICAN:ELMD) Stock Price Passes Above 200 Day Moving Average of $0.00
Electromed, Inc. (NYSEAMERICAN:ELMD) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $15.62. Electromed shares last traded at $15.07, with a volume of 64,900...
Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q3 2020 Results - Earnings Call Transcript
Electromed, Inc. (NYSEMKT:ELMD) Q3 2020 Earnings Conference Call May 13, 2020 08:30 ET Company Participants Kalle Ahl - Investor Relations Kathleen Skarvan - Pr
Electromed, Inc. Announces Fiscal 2020 Third Quarter Financial Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended March 31, 2020 (“Q3 FY 2020”). Q3 FY 2020 Highlights Net revenue...
UPS AND DOWNS
NEW YORK (AP) —The following list shows the NYSE MKT-listed stocks that have gone up the most and down the most based on percent of change for 2019. No securities trading below 1000 shares are included. Net and percentage change...
Electromed, Inc. Schedules its Third Quarter Fiscal 2020 Financial Results Conference Call for May 13, 2020 at 8:30 a.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2020 third quarter ended March 31, 2020...
5 Themes (& Picks) for Coronavirus Investing
Coronavirus is going to be around for a while, so let's use it to define our investment strategies.
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
5 Stocks With Recent Price Strength Amid Coronavirus Logjam
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Source: https://incomestatements.info
Category: Stock Reports